Going beyond Commitment,

SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suven.com website: www.suven.com

	Particulars	Eor	the Quarter end	led	For the Nine Months ended		dian Rupees in lakhs For the Year
SI. No.		31-Dec-2017 30-Sep-2017 31-Dec-2016			31-Dec-2017 31-Dec-2016		Ended 31-Mar-2017
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
	(a) Net sales/income from operations (Refer Note 3)	16,273.88	10,409.95	11,539.43	40,428.73	36,417.10	53,916.7
	(b) Other operating income	91.85	275.93	15.89	724.78	15.89	531.04
	Total Revenue from operations	16,365.73	10,685.88	11,555.32	41,153.51	36,432.99	54,447.78
2	Other Income	328.95	513.23	490.15	1,404.47	1,615.40	2,109.2
	Total Income (1+2)	16,694.68	11,199.11	12,045.47	42,557.98	38,048.39	56,557.0
3	Expenses						
	(a) Cost of materials consumed	5,104.86	4,218.13	3,852.71	13,006.52	11,245.30	15,480.6
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(185.72)	(3,189.36)	(1,607.90)	(3,602.25)	(2,530.55)	(295.9
	(d) Employee benefits expense	1,481.60	1,267.76	1,262.91	4,315.58	3,610.93	5,064.4
	(e) Finance costs	115.16	93.58	126.47	335.75	409.76	566.5
	(f) Depreciation and amortisation expenses	541.66	533.99	487.20	1,594.85	1,423.00	2,141.3
	(g) Manufacturing expenses	2,379.39	2,101.03	1,975.74	6,670.79	5,625.94	8,157.3
	(h) Research & Development expenses	1,387.83	1,166.13	1,635.97	4,155.15	4,570.34	6,494.0
	(i) Other expenses	1,058.62	622.66	749.64	2,440.34	2,193.32	3,012.8
	Total expenses	11,883.40	6,813.92	8,482.74	28,916.73	26,548.04	40,621.3
4	Profit before exceptional items and tax (1+2-3)	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.6
5	Exceptional Items	-	-	-			
6	Profit before tax (4 - 5)	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.6
7	Tax Expenses						
	(a) Current tax	1,014.68	592.11	949.47	2,739.56	3,131.60	3,275.0
8	(b) Deferred tax	336.78	618.35	186.19	1,310.07	28.35	313.2
	Net Profit for the period / year (6-7)	3,459.82	3,174.73	2,427.07	9,591.62	8,340.40	12,347.3
9	Other Comprehensive Income						
9.A	(i) Items that will not be reclassified to profit or loss	(3.73)	(3.72)	(11.31)	(11.18)	(33.92)	(14.9
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.29	1.29	-	3.87	-	5.1
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(2.44)	(2.43)	(11.31)	(7.31)	(33.92)	(9.7
	Total Comprehensive Income (8+9)	3,457.38	3,172.30	2,415.76	9,584.31	8,306.48	12,337.6
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.8
11	Earning Per Share (EPS) for continuing operation (face value of						
	Rs.1/- each):						
	a) Basic	2.72	2.49	1.90	7.53	6.53	9.6
	b) Diluted	2.72	2.49	1.90	7.53	6.53	9.6

		SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES							
	PARTICULARS	For the Quarter Ended			For the Nine Months ended		Ended		
		31-Dec-2017 Un-audited	30-Sep-2017	31-Dec-2016 Un-audited	31-Dec-2017	31-Dec-2016 Un-audited	31-Mar-2017 Audited		
1	SEGMENT REVENUE	Ull-audited	Un-audited	On-addited	Un-audited	Ull-audited	Auditeu		
-	a) Manufacturing (CRAMS)	15,693.88	10,026.47	10,682.46	39,051.11	34,169.91	51,670.07		
	b) Services (DDDSS)	671.85	659.41	856.99	2,102.40	2,263.08	2,777.72		
	c) Research & Development	-	-	-	2,102.40	2,205.00	2,777.7		
	Total	16,365.73	10,685.88	11,539.45	41,153.51	36,432.99	- 54,447.7		
	Less: Inter Segment Revenue	10,303.73	10,005.00	11,555.45	41,155.51	30,432.33	54,447.70		
	Net Sales/Income from Operations	- 16,365.73	- 10,685.88	- 11,539.45	- 41,153.51	- 36,432.99	54,447.7		
2	· · ·	10,305.75	10,005.00	11,559.45	41,155.51	50,452.99	54,447.70		
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)	C 444 25	E 242 42	4 000 12	17 520 24	45 202 47	21 (24 0)		
	a) Manufacturing (CRAMS)	6,444.25	5,312.13	4,999.12	17,539.24	15,292.47	21,634.8		
	b) Services (DDDSS)	267.76	319.36	439.15	992.37	1,201.13	1,476.8		
	c) Research & Development	(1,387.83)		(1,635.97)	., .	(4,570.34)	(6,494.0		
	ΤΟΤΑΙ	-,	4,465.35	3,802.30	14,376.46	11,923.26	16,617.5		
	Less: i) Finance Cost	72.41	74.19	93.12	233.71	301.37	376.3		
	ii) Other Un-allocable expenditure /(income), net	440.49	5.97	146.45	501.50	121.54	305.5		
	Total Profit Before Tax	4,811.28	4,385.19	3,562.73	13,641.25	11,500.35	15,935.6		
3	SEGMENT ASSETS :								
	a) Manufacturing (CRAMS)	56,835.94	53,711.58	51,397.78	56,835.94	51,397.78	43,886.9		
	b) Services (DDDSS)	4,174.47	4,077.86	2,693.72	4,174.47	2,693.72	2,828.6		
	c) Research & Development	3,117.69	2,896.37	2,489.66	3,117.69	2,489.66	2,609.6		
	d) Un allocated	35,007.49	35,647.25	29,713.48	35,007.49	29,713.48	38,291.8		
	ΤΟΤΑ	99,135.59	96,333.06	86,294.64	99,135.59	86,294.64	87,616.9		
4	SEGMENT LIABILITIES :								
	a) Manufacturing (CRAMS)	9,663.85	9,984.93	8,727.74	9,663.85	8,727.74	8,547.8		
	b) Services (DDDSS)	498.66	574.83	491.00	498.66	491.00	370.2		
	c) Research & Development	1,866.63	2,253.38	2,113.04	1,866.63	2,113.04	1,848.1		
	d) Un allocated	856.23	925.45	803.03	856.23	803.03	687.2		
	ΤΟΤΑ	12,885.37	13,738.59	12,134.81	12,885.37	12,134.81	11,453.5		

Notes:

1) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 30th January, 2018 and the same reviewed by the Statutory Auditors.

3) Excise duty on sales was included under Revenue from operations and disclosed separately under expenses up to all reporting periods ending 30-June-2017. Post implementation of Goods and Service Tax (GST) Act w.e.f. 1st July, 2017 the revenue from operations is reported for the period ended 31-Dec-2017 is net of GST and hence to that extent not comparable.

- 4) The corresponding previous period figures have been regrouped / reclassified where ever necessary.
- 5) The Board has declared an Interim Dividend of Rs. 1.50 per equity share of face value of Rs. 1.00 each for the financial year 2017-18, The outflow on account of Interim dividend including dividend distribution tax is Rs. 2297.91 lakhs.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad Date: 30th January, 2018 VENKAT JASTI Chairman & CEO DIN: 00278028